Akston Biosciences Corp., pet medicines company, has filed paperwork with the U.S. Securities and Exchange Commission to ...

The U.S. IPO market roared back in 2025, as the 176 initial public offerings during the first half of the year matched the ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins the ...

So much for the dog days of summer. During July, 6 more biotech companies took a running leap through the wide-open IPO window, joining a growing pool of newly made ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Ming Yu was set up in 2018 by Cao Guoqing, a biochemist with an international profile in cutting-edge drug research. Cao ...

Not only has the window for biotech initial public offerings (IPOs) remained wide open so far this year, but also the after-market performance of the newly minted public companies has been nothing ...

Jyong Biotech aims to raise $18.8 million in a US IPO. The company develops plant-based treatments for urinary diseases but faces FDA efficacy doubts and high legal cost exposure. Financially, Jyong ...